Minireviews
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Cardiol. Sep 26, 2013; 5(9): 347-354
Published online Sep 26, 2013. doi: 10.4330/wjc.v5.i9.347
Subcutaneous implantable defibrillator: State-of-the art 2013
Finn Akerström, Miguel A Arias, Marta Pachón, Alberto Puchol, Jesús Jiménez-López
Finn Akerström, Miguel A Arias, Marta Pachón, Alberto Puchol, Jesús Jiménez-López, Cardiac Arrhythmia and Electrophysiology Unit, Department of Cardiology, Hospital Virgen de la Salud, 45004 Toledo, Spain
Author contributions: All authors contributed to the paper.
Correspondence to: Dr. Miguel A Arias, MD, PhD, Cardiac Arrhythmia and Electrophysiology Unit, Department of Cardiology, Hospital Virgen de la Salud, Avda, Barber 30, Planta Semisótano, 45004 Toledo, Spain. maapalomares@secardiologia.es
Telephone: +34-92-5265492 Fax: +34-92-5265492
Received: June 26, 2013
Revised: August 1, 2013
Accepted: August 16, 2013
Published online: September 26, 2013
Processing time: 91 Days and 22.2 Hours
Core Tip

Core tip: The subcutaneous implantable cardioverter-defibrillator (S-ICD) has recently been commercialized in Europe, New Zealand and the United States and implanted in over 2000 patients so far worldwide. It represents an important innovation in the field of device therapy since it avoids the potential periprocedural and long-term complications associated with endovascular leads used with conventional transvenous ICDs. Future studies will better define patient target groups and thereby establish the therapeutic potential of this new device technology.